98 related articles for article (PubMed ID: 32216946)
1. A Novel Intergenic LSM14A-RET Fusion Variant in a Patient With Lung Adenocarcinoma.
Lv Y; Ling F; Zhang J; Xiao M; Mao W
J Thorac Oncol; 2020 Apr; 15(4):e52-e53. PubMed ID: 32216946
[No Abstract] [Full Text] [Related]
2. Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib.
Zheng Q; Fang W; Huang Y; Gan J; Zhang L
J Thorac Oncol; 2020 Aug; 15(8):e132-e133. PubMed ID: 32718536
[No Abstract] [Full Text] [Related]
3. The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
Zhu YC; Wang WX; Zhang QX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
Clin Lung Cancer; 2019 Jan; 20(1):e73-e76. PubMed ID: 30366769
[No Abstract] [Full Text] [Related]
4. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
5. A novel TNIP2-RET fusion identified in a patient with mucinous adenocarcinoma of the lung.
Ren P; Luo N; Qi Y; Wu Y; Jin M
Lung Cancer; 2021 Mar; 153():179-181. PubMed ID: 33478856
[No Abstract] [Full Text] [Related]
6. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T
Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
[TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma.
Go H; Jung YJ; Kang HW; Park IK; Kang CH; Lee JW; Ju YS; Seo JS; Chung DH; Kim YT
Lung Cancer; 2013 Oct; 82(1):44-50. PubMed ID: 23932363
[TBL] [Abstract][Full Text] [Related]
9. Breaking down RET breakpoints in lung adenocarcinoma.
Watanabe H; Brooks AN; Meyerson M
J Thorac Oncol; 2014 May; 9(5):590-2. PubMed ID: 24722148
[TBL] [Abstract][Full Text] [Related]
10. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
[TBL] [Abstract][Full Text] [Related]
11. TPR-RET: A novel RET rearrangement in a lung adenocarcinoma patient with head and neck metastases.
Li S; Tian J; Chen D; Li S; He X
Oral Oncol; 2020 Sep; 108():104929. PubMed ID: 32741727
[No Abstract] [Full Text] [Related]
12. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
[TBL] [Abstract][Full Text] [Related]
13. A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor.
Qiu H; Li Q; Xiao Y; Wu D; Meng R
J Thorac Oncol; 2021 Apr; 16(4):e21-e23. PubMed ID: 33781445
[No Abstract] [Full Text] [Related]
14. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
Fei X; Zhu L; Zhou H; Qi C; Wang C
J Thorac Oncol; 2019 Sep; 14(9):e191-e193. PubMed ID: 31445731
[No Abstract] [Full Text] [Related]
15. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma.
Mizukami T; Shiraishi K; Shimada Y; Ogiwara H; Tsuta K; Ichikawa H; Sakamoto H; Kato M; Shibata T; Nakano T; Kohno T
J Thorac Oncol; 2014 May; 9(5):622-30. PubMed ID: 24722152
[TBL] [Abstract][Full Text] [Related]
17. Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene.
Wu H; Shih JY; Yang JC
J Thorac Oncol; 2015 Sep; 10(9):e95-e96. PubMed ID: 26291023
[No Abstract] [Full Text] [Related]
18. Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Huang Q; Schneeberger VE; Luetteke N; Jin C; Afzal R; Budzevich MM; Makanji RJ; Martinez GV; Shen T; Zhao L; Fung KM; Haura EB; Coppola D; Wu J
Mol Cancer Ther; 2016 Oct; 15(10):2521-2529. PubMed ID: 27496134
[TBL] [Abstract][Full Text] [Related]
19. WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
Velcheti V; Madison R; Ali SM; Schrock AB
J Thorac Oncol; 2018 Jul; 13(7):e122-e123. PubMed ID: 29935851
[No Abstract] [Full Text] [Related]
20. A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.
Saito M; Ishigame T; Tsuta K; Kumamoto K; Imai T; Kohno T
Carcinogenesis; 2014 Nov; 35(11):2452-6. PubMed ID: 25064355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]